Effect of pectin and kaolin on bioavailability of co-trimoxazole suspension.
Bioavailability of co-trimoxazole suspension was determined with and without concurrent administration of pectin and kaolin in 8 volunteers. Twenty ml suspension of co-trimoxazole containing 160 mg trimethoprim (TMP) and 800 mg sulphamethoxazole (SMX) and co-trimoxazole suspension along with 20 ml of pectin-kaolin suspension were administered in a random order with 7 days interval. Plasma estimation of trimethoprim and sulphonamide was carried out at serial intervals. Area under curve (AUC) and Cmax of TMP were significantly higher when co-trimoxazole suspension alone was used. No statistically significant changes were observed in case of sulphamethoxazole. Clinical study is necessary to verify whether concurrent administration of co-trimoxazole and pectin-kaolin leads to loss of antibacterial efficacy.
D000328:Adult; D000890:Anti-Infective Agents / Q000378:metabolism*; D001682:Biological Availability; D004338:Drug Combinations / Q000378:metabolism; D004347:Drug Interactions; D006801:Humans; D007616:Kaolin / Q000494:pharmacology*; D010368:Pectins / Q000494:pharmacology*; D011897:Random Allocation; D013420:Sulfamethoxazole / Q000378:metabolism*; D013535:Suspensions; D014295:Trimethoprim / Q000378:metabolism*; D015662:Trimethoprim, Sulfamethoxazole Drug Combination
D000890:Anti-Infective Agents; D004338:Drug Combinations; D013535:Suspensions; D007616:Kaolin; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D010368:Pectins; D014295:Trimethoprim; D013420:Sulfamethoxazole